Pentosan polysulfate - Urigen Pharmaceuticals

Drug Profile

Pentosan polysulfate - Urigen Pharmaceuticals

Alternative Names: URG 501

Latest Information Update: 14 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Urigen Pharmaceuticals
  • Class Anti-inflammatories; Anticoagulants; Antihyperlipidaemics; Antiretrovirals; Antithrombotics; Antivirals; Glycosaminoglycans; Polymers; Polysaccharides; Small molecules; Sulfuric acids
  • Mechanism of Action Cell membrane permeability inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Interstitial cystitis

Most Recent Events

  • 07 Oct 2016 Preclinical trials in Interstitial cystitis in USA (Intraperitoneal) before October 2016 (Urigen Pharmaceuticals pipeline, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top